Makara Gergely M, Athanasopoulos John
Merck Research Laboratories, Merck & Co., RY80Y-325, Rahway, New Jersey 07065, USA.
Curr Opin Biotechnol. 2005 Dec;16(6):666-73. doi: 10.1016/j.copbio.2005.10.007. Epub 2005 Oct 28.
Affinity technologies have been applied at several stages of the drug discovery process, ranging from target identification and purification to the identification of preclinical candidates. The detection of ligand-macromolecule interactions in lead discovery is the best studied and most powerful of these techniques. Although affinity methods have been in widespread use for about a decade, only recently have many reports emerged on their utility. Primary affinity screens of large libraries of small molecules or fragments have begun to produce results for challenging targets. Furthermore, in secondary assays affinity methods are opening new avenues to tackle important medicinal chemistry tasks.
亲和技术已应用于药物发现过程的多个阶段,从靶点识别与纯化到临床前候选药物的识别。在先导化合物发现中检测配体 - 大分子相互作用是这些技术中研究得最充分且最强大的。尽管亲和方法已广泛使用约十年,但直到最近才有许多关于其效用的报道。对小分子或片段的大型文库进行的初步亲和筛选已开始为具有挑战性的靶点产生结果。此外,在二次检测中,亲和方法为解决重要的药物化学任务开辟了新途径。